Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
Disclosed are novel novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter “Compound A-1,4-dioxane/water solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles (° 28), when measured using Cu Ku radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5.
1. A crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α radiation, at about 5.9, 16.1, 17.4, 18.0, 20.4, and 23.7° 2θ.
2. A crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 2 .
3. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum containing peaks at about 737, 1161, 1303, 1595, 1611, and 1654 cm −1 .
4. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum substantially in accordance with FIG. 7 .
5. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
6. A method of preparing a pharmaceutical composition comprising admixing the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
7. The crystalline form of claim 1 , wherein the crystalline form differential scanning calorimetry themogram profile is substantially in accordance with FIG. 11 .
8. The pharmaceutical composition of claim 5 , further comprising a non-steroidal anti-inflammatory agent.
9. The crystalline form according to claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α radiation, at about 8.6, 12.1, 12.7, 16.9, 17.8, 20.6, 21.7, 22.6, 23.9, 24.3, 25.9, 26.3, 26.5, 26.9, 27.9, 30.9, and 38.6° 2θ.
10. The crystalline form according to claim 3 , wherein the crystalline form provides a Raman spectrum containing peaks at about 655, 668, 804, 1079, 1099, 1123, 1229, 1465, and 1537 cm −1 .
11. The crystalline form of claim 2 , wherein the crystalline form provides a Raman spectrum substantially in accordance with FIG. 7 .
12. The crystalline form of claim 2 , wherein the crystalline form differential scanning calorimetry themogram profile is substantially in accordance with FIG. 11 .
13. A method of preparing a pharmaceutical composition comprising admixing the crystalline form of claim 2 and a pharmaceutically acceptable carrier.
14. The crystalline form of claim 1 , wherein the crystalline form thermogravimetric analysis thermogram profile is substantially in accordance with FIG. 15 .
15. The crystalline form of claim 2 , wherein the crystalline form thermogravimetric analysis thermogram profile is substantially in accordance with FIG. 15 .
16. A pharmaceutical composition comprising the crystalline form of claim 2 and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , further comprising a non-steroidal anti-inflammatory agent.